Evidence map›Paper›PMID 35054719›Full record

ArticlePolymers2022

Taking Advantage of Phosphate Functionalized Waterborne Acrylic Binders to Get Rid of Inhibitors in Direct-to-Metal Paints.

Stefano Chimenti, Marco Cerra, Tito Zanetta, Jose Ramon Leiza, María Paulis

Abstract read
In one paragraph

Article in Polymers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stefano ChimentiPOLYMAT, Kimika Aplikatua Saila, Kimika Fakultatea, University of the Basque Country UPV/EHU, Joxe Mari Korta Zentroa, Tolosa Hiribidea 72, 20018 Donostia-San Sebastián, Spain.
Marco CerraVinavil SPA, Via Toce, 7, 28844 Villadossola, Italy.
Tito ZanettaVinavil SPA, Via Toce, 7, 28844 Villadossola, Italy.
Jose Ramon LeizaPOLYMAT, Kimika Aplikatua Saila, Kimika Fakultatea, University of the Basque Country UPV/EHU, Joxe Mari Korta Zentroa, Tolosa Hiribidea 72, 20018 Donostia-San Sebastián, Spain.ORCID 0000-0001-9936-7539
María PaulisPOLYMAT, Kimika Aplikatua Saila, Kimika Fakultatea, University of the Basque Country UPV/EHU, Joxe Mari Korta Zentroa, Tolosa Hiribidea 72, 20018 Donostia-San Sebastián, Spain.ORCID 0000-0002-7000-1231

Funding

Basque Government IT-999-16Ministry of Economy, Industry and Competitiveness CTQ-2017287841-R
6 · The paper itself

Abstract

In this paper, two phosphate functionalized acrylic binders are formulated to yield direct-to-metal paints without using corrosion inhibitors. The difference between both binders is the addition of polystearylacrylate crystalline nanodomains in one of them, and an amorphous methyl methacylate-co-butyl acrylate copolymer in the other. The water sensitivity, mechanical stability, adhesion, and the performance of the paints against corrosion (high humidity resistance, accelerated weathering, and salt-spray tests) are assessed and compared with a DTM paint formulated from a commercial binder. The performance of both phosphate functionalized paints formulated without corrosion inhibitors in high humidity and weathering tests is superior to the commercial DTM paint formulated without corrosion inhibitors and similar to the DTM paint formulated with them. Furthermore, the paint based on the amorphous copolymer binder provides significantly good performance in the salt spray test (even superior to that of the DTM paint formulated with corrosion inhibitors).

Indexed as

corrosion protectiondirect-to-metal paintinhibitor-freepaint formulationwaterborne phosphate-stabilized binder

Identifiers

PMID35054719
PMCPMC8778291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.